The FDA has given 510(k) clearance for peripheral atherectomy products, Turbo-Tandem and Turbo Elite, from Spectranetics, for the treatment of...
Abbott and Tandem Diabetes Care, Inc. a leading insulin delivery and diabetes technology company, announced that the t:slim X2 insulin pump with Control-IQ technology is the first automated insulin delivery (AID) system to integrate with the newly available FreeStyle Libre 2 Plus sensor, Abbott’s latest continuous glucose monitoring (CGM) technology.
Boston Scientific has entered into a definitive agreement to acquire the interventional radiology portfolio of CeloNova Biosciences, a San Antonio-based...
Takeda announced late-breaking data from the Phase III GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating Entyvio (vedolizumab) achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) Acute Graft-Versus-Host Disease (aGvHD)-free survival by Day 180 after allo-HSCT (Allogeneic Hematopoietic Stem Cell Transplantation) with no relevant differences in safety profile versus placebo
Actinium Pharmaceuticals, Inc reported new analyses from the positive Phase III SIERRA trial of Iomab-B in oral presentations at the at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT (American Society for Transplantation and Cellular Therapy and CIBMTR (Center for International Blood and Marrow Transplant Research)
Gamida Cell announced that two oral presentations and a poster presentation highlighting Gamida Cell’s investigational product candidate omidubicel at the 2023 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT).
Daiichi Sankyo announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) positive
FMS-like tyrosine kinase 3- internal tandem duplication (FLT3-ITD) remains as one of the most frequently mutated genes in acute myeloid leukemia (AML), especially in those with normal cytogenetics. The FLT3-ITD and FLT3-TKD...
Internal tandem duplications and tyrosine kinase mutations in the fms-like tyrosine kinase 3 (FLT3) receptor can occur in acute myeloid leukemia (AML) and portend a poor prognosis.
Astellas Pharma Inc. and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) announced topline results from the Phase III MORPHO clinical trial evaluating gilteritinib as a maintenance therapy following allogeneic hematopoietic stem cell transplantation (HSCT) for patients with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutated acute myeloid leukemia (AML).